Unknown

Dataset Information

0

Blockage of neddylation modification stimulates tumor sphere formation in vitro and stem cell differentiation and wound healing in vivo.


ABSTRACT: MLN4924, also known as pevonedistat, is the first-in-class inhibitor of NEDD8-activating enzyme, which blocks the entire neddylation modification of proteins. Previous preclinical studies and current clinical trials have been exclusively focused on its anticancer property. Unexpectedly, we show here, to our knowledge for the first time, that MLN4924, when applied at nanomolar concentrations, significantly stimulates in vitro tumor sphere formation and in vivo tumorigenesis and differentiation of human cancer cells and mouse embryonic stem cells. These stimulatory effects are attributable to (i) c-MYC accumulation via blocking its degradation and (ii) continued activation of EGFR (epidermal growth factor receptor) and its downstream pathways, including PI3K/AKT/mammalian target of rapamycin and RAS/RAF/MEK/ERK, via inducing EGFR dimerization. Finally, MLN4924 accelerates EGF-mediated skin wound healing in mouse and stimulates cell migration in an in vitro culture setting. Taking these data together, our study reveals that neddylation modification could regulate stem cell proliferation and differentiation and that a low dose of MLN4924 might have a therapeutic value for stem cell therapy and tissue regeneration.

SUBMITTER: Zhou X 

PROVIDER: S-EPMC4889367 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Blockage of neddylation modification stimulates tumor sphere formation in vitro and stem cell differentiation and wound healing in vivo.

Zhou Xiaochen X   Tan Mingjia M   Nyati Mukesh K MK   Zhao Yongchao Y   Wang Gongxian G   Sun Yi Y  

Proceedings of the National Academy of Sciences of the United States of America 20160509 21


MLN4924, also known as pevonedistat, is the first-in-class inhibitor of NEDD8-activating enzyme, which blocks the entire neddylation modification of proteins. Previous preclinical studies and current clinical trials have been exclusively focused on its anticancer property. Unexpectedly, we show here, to our knowledge for the first time, that MLN4924, when applied at nanomolar concentrations, significantly stimulates in vitro tumor sphere formation and in vivo tumorigenesis and differentiation of  ...[more]

Similar Datasets

| S-EPMC6862758 | biostudies-literature
| S-EPMC5333757 | biostudies-other
| S-EPMC3448595 | biostudies-other
| S-EPMC3955965 | biostudies-literature
| S-EPMC5733167 | biostudies-literature
| S-EPMC3686062 | biostudies-literature
| S-EPMC4715972 | biostudies-literature
| S-EPMC6121836 | biostudies-literature
| S-EPMC6376177 | biostudies-literature
| S-EPMC3460460 | biostudies-literature